Performance of recalibrated ReFacto® laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto® (B-domain deleted recombinant factor VIII)

Haemophilia

Volumn 15, Issue 3, 2009, Pages 779-787

  Santoro, C ^a   Iorio, A ^b   Ferrante, F ^b   Pallotta, A ^a   Pignoloni, P ^a   Biondo, F ^a   Agnelli, G ^b   Mazzucconi, M G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

B domain deleted recombinant FVIII; Haemophilia; Pharmacokinetics; ReFacto

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; HEMOPHILIA A; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REFERENCE VALUE; SCHOOL CHILD; SENSITIVITY ANALYSIS; STANDARDIZATION; STEADY STATE;

ADOLESCENT; BIOLOGICAL ASSAY; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION TESTS; CHILD; CHROMOGENIC COMPOUNDS; FACTOR VIII; HEMOPHILIA A; HUMANS; INFUSIONS, INTRAVENOUS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; PEPTIDE FRAGMENTS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 65449137867     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.01983.x     Document Type: Article

References (31)

1. Morfini M. Comparative pharmacokinetic studies in haemophilia. Haemophilia 2002; 8: 30-3.
2. Berntorp E, Bjorkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 9: 353-9.
3. Brinkhous K, Sandberg H, Widlund L, et al. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. Semin Thromb Hemost 2002; 28: 269-72.
4. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11: 571-82.
5. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
6. Pittman DD, Marquette KA, Kaufman RJ. Role of the B domain for factor VIII and factor V expression and function. Blood 1994; 84: 4214-25.
7. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939-42.
8. Plantier JL, Guillet B, Ducasse C, et al. B-domain deleted factor VIII is aggregated and degraded through proteasomal and lysosomal pathways. Thromb Haemost 2005; 93: 824-32.
9. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38: 52-9.
10. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38: 44-51.
11. Lee C. The use of recombinant factor VIII products in previously treated patients with hemophilia A: Pharmacokinetics, efficacy, safety, and inhibitor development. Semin Thromb Hemost 2002; 28: 241-6.
12. Lusher JM. First and second generation recombinant factor VIII concentrates in previously untreated patients: Recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost 2002; 28: 273-6.
13. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
14. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis-a meta-analysis. Haemophilia 2003; 9: 251-60.
15. Kessler CM, Gill JC, White GC, et al. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: A randomized, three-way crossover study. Haemophilia 2005; 11: 84-91.
16. Di Paola J, Smith MP, Klamroth R, et al. ReFacto and Advate: A single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007; 13: 124-30.
17. Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 2004; 126: 398-404.
18. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity-assay discrepancies. Haemophilia 1998; 4: 641-5.
19. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 13-23.
20. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28: 247-56.
21. Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A, Mannucci PM. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost 2003; 1: 2283-9.
22. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
23. Khrenov AV, Ananyeva NM, Saenko EL. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X. Blood Coagul Fibrinolysis 2006; 17: 379-88.
24. Ingerslev J, Jankowski MA, Weston SB, Charles LA. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004; 2: 623-8.
25. Hubbard AR, Sands D, Sandberg E, Seitz R, Barrowcliffe TW. A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost 2003; 90: 1088-93.
26. EMEA Public statement on ReFacto (moroctocog alpha). CPMP/2337/03. Embargo date 27-5-2003 (last accessed on 14 September 2008).
27. Lee M, Morfini M, Schulman S, Ingerslev J and the factor VIII/Factor IX Scientific Standardisation Committee of the International Society for Thrombosis and Haemostasis. Scientific and Standardisation Committee Communication: The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. ISTH Website, 21 March 2001 (last accessed on 14 september 2008).
28. Ingram GI. Blood-coagulation factor 8: Genetics, physiological control, and bioassay. Adv Clin Chem 1965; 8: 189-236.
29. Nilsson IM, Hedner U. Characteristics of various factor VIII concentrates used in treatment of haemophilia A. Br J Haematol 1977; 37: 543-57.
30. Lambert T, Guerois C, Gay V, et al. Factor VIII recovery after a single infusion of recalibrated ReFacto in 14 severe haemophilia A patients. Haemophilia 2007; 13: 357-60.
31. Caron C, Dautzenberg MD, Delahousse B, et al. A blinded in vitro study with Refacto mock plasma samples: Similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution. Haemophilia 2002; 8: 639-43.